SLC5A2 and hydrops fetalis: Current guideline-directed therapies, such as SGLT2 inhibitors, have already established the feasibility of metabolic modulation in HF, while exercise, ω-3 PUFA, and L-carnitine supplementation provide additional support through effects on mitochondrial and FAO pathways.